---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Mechanism of action"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Mechanism of action. Topics: Vector construct: self-complementary AAV9 encoding a miniaturized MECP2 with the miRARE element, Intended mechanism: one-time delivery of a functional MECP2 to central nervous system cells, Rationale for autoregulation: risks of MeCP2 under-expression and over-expression, miRARE: silencing in cells with normal MeCP2 function and expression in MeCP2-deficient cells, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Vector construct: self-complementary AAV9 encoding a miniaturized MECP2 with the miRARE element

> “recombinant, self-complementary (dimeric), non-replicating adeno-associated virus serotype 9 (scAAV9) vector encoding a miniaturised form of human methyl-CpG binding protein 2 (MECP2) containing the methyl-CpG-binding domain (MBD) and the NCoR/SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) interaction domain (NID), under the control of a fragment of the mouse MECP2 promoter. The 3' untranslated region is designed to decrease protein expression through RNA interference by containing a microRNA (miR) Responsive Auto-Regulatory Element (miRARE) inserted into the replication dependent histone 1 (RDH1) polyadenylation region. The construct is flanked by adeno-associated virus 2 (AAV2) inverted terminal repeats (ITRs)”

Source: [FDA UNII NVK87P6NXW](https://precision.fda.gov/uniisearch/srs/unii/NVK87P6NXW)

<a id="topic-2.1.2.6.1-2"></a>

### Intended mechanism: one-time delivery of a functional MECP2 to central nervous system cells

> “TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.”
> “Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS.”
> “TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-2.1.2.6.1-3"></a>

### Rationale for autoregulation: risks of MeCP2 under-expression and over-expression

> “Because of the risks associated with both under- and over-expression of MeCP2, we have combined high-throughput microRNA, or miRNA, profiling and genome mining to create miRNA-Responsive Auto-Regulatory Element, or miRARE, our novel miRNA target panel.”
> “The miRARE element includes binding sites for endogenous miRNA, which are responsive to MeCP2 levels to prevent overexpression.”
> “By increasing MECP2 levels in MECP2 deficient cells and maintaining healthy levels of MECP2 output of healthy cells, TSHA-102 has demonstrated the ability to produce and maintain safe transgene expression levels in the CNS.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.1.2.6.1-4"></a>

### miRARE: silencing in cells with normal MeCP2 function and expression in MeCP2-deficient cells

> “TSHA-102 carries a 3’ element, the miR-Responsive Auto-Regulatory Element (miRARE), designed to silence transgene expression in cells with normal MeCP2 function and permit expression in MeCP2-deficient cells”
> “miRARE is designed to SILENCE miniMECP2 transgene expression in healthy, MeCP2+ cells”
> “miRARE is designed to ENABLE miniMECP2 transgene expression in MeCP2-deficient cells”

Source: [Haque et al. (2025)](https://tayshagtx.com/wp-content/uploads/rAAV9-Vector-Biodistribution-in-Brain-and-Spinal-Cord-via-Lumbar-Intrathecal-Infusion-in-Nonhuman-Primates-NHP-Assessing-the-Administration-Route-Leveraged-in-TSHA-102-Rett-Syndrome-Clinical-Trials.pdf)

<a id="topic-2.1.2.6.1-5"></a>

### Proposed feedback mechanism: microRNA seed sequences in the 3 prime untranslated region

> “miRNA target sites (seeds; red) engineered into the miRARE are proposed to silence transgene expression in response to cellular MeCP2 function.”
> “The miniMECP2 3’UTR carries seeds for at least 10 miRNAs, including 6 in the miRARE.”

Source: [Haque et al. (2023)](https://tayshagtx.com/wp-content/uploads/The-microRNA-responsive-autoregulatory-element-from-TSHA-102-for-Rett-Syndrome-modulates-therapeutic-transgene-expression-in-response-to-cellular-MeCP2-in-mouse-and-human-cell-lines.pdf)

<a id="topic-2.1.2.6.1-6"></a>

### Self-complementary genome: a transcription-ready transgene

> “In contrast to ssAAV vectors that require conversion of the single-stranded DNA to double-stranded DNA prior to expression, TSHA-102 contains complementary strands of the MECP2 transgene, delivering a transcription-ready transgene to MeCP2-deficient cells for enhanced stability and efficiency”
> “A miRNA-Responsive Auto-Regulatory Element (miRARE) further refines expression by silencing transgene expression in MeCP2-healthy cells while permitting expression in MeCP2-deficient cells”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

<a id="topic-2.1.2.6.1-7"></a>

### Transgene: truncated MECP2 retaining the methyl-CpG-binding and NCoR/SMRT interaction domains

> “TSHA-102 is an investigational AAV9 vector containing a truncated, but therapeutically active, version of the human MECP2 gene (miniMECP2), a novel miRNA binding site panel (miRARE), self-complementary AAV2 inverted terminal repeat elements, and a fragment of the endogenous mouse MECP2 promoter that contains both regulatory and putative silencer elements (MeP426)”

Source: [Prasad et al. (2022a)](https://tayshagtx.com/wp-content/uploads/ASGCT-2022-Safety-and-Biodistribution-Assessment-in-Non-Human-Primates-NHP-of-a-miniMECP2-AAV9-Vector-for-Gene-Replacement-Therapy-of-Rett-Syndrome.pdf)

> “A truncated MeCP2 protein retaining the essential methyl-CpG-binding domain (MBD) and the transcriptional repressor NCoR/SMRT interaction domain (NID) restored a normal phenotype in Mecp2-/Y mice and showed comparable functionality to full-length MeCP2”

Source: [Haque et al. (2026b)](https://tayshagtx.com/wp-content/uploads/ASGCT-Superior-expression-of-self-complementary-AAV-and-comparable-functionality-of-mini-and-full-length-MECP2-support-the-design-of-TSHA-102-gene-therapy-for-Rett-syndrome.pdf)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
